Synvivia engineers molecules to reprogram cells, enabling precise control of biological functions through small molecules. This technology allows for targeted manipulation of cellular behavior, addressing challenges in synthetic biology and therapeutic development.
Funding
$375.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FGNSFounders
Product
Problem
Current methods of controlling cell behavior in synthetic biology and therapeutic development lack the precision needed for targeted manipulation of cellular functions. Existing technologies struggle to achieve fine-tuned control over specific biological processes within cells.
Solution
Synvivia develops engineered molecules that enable the precise reprogramming of cells, allowing for targeted control of biological functions through small molecules. Their technology facilitates the manipulation of cellular behavior by creating custom molecules that interact with specific cellular pathways. This approach allows researchers and drug developers to influence cellular processes with greater accuracy and control compared to traditional methods. Synvivia's platform offers a way to design and implement sophisticated control mechanisms within cells, opening new possibilities for synthetic biology and therapeutic interventions.
Target Audience
Synvivia's primary customers are researchers and drug developers in the fields of synthetic biology and therapeutics.
Features
- Engineered molecules for reprogramming cellular behavior
- Precise control of biological functions through small molecules
- Targeted manipulation of cellular pathways
- Custom molecule design for specific cellular interactions